Boston-based Elucid announced a $55M Series D on Sept 3, 2026, led by IAG Capital Partners and Elevage. Its AI software analyzes cardiovascular imaging to detect coronary artery disease.
Why this matters for founders
A signal that FDA-adjacent clinical AI is still drawing large late-stage checks; healthtech founders can cite it when framing regulated-AI raises.
Source: Tech Startups
Related updates
More that helps you.
Stockholm's Tandem Health raises $100M Series B for an AI clinical operating system
Tandem Health raised EUR 86.49 million (about $100 million) in a Series B led by the EQT-managed Scaleup Europe Fund, announced September 14, 2026. The startup is expanding from AI…
AI health startup Forus raises $150M at $3B value to automate drug access
Forus (formerly Tandem) raised a $150 million Series C at a $3 billion valuation announced September 8, 2026, led by Bain Capital Ventures with Accel, Thrive Capital, General Catal…
Intrepid Growth closes US$525M debut fund to back AI founders
Toronto- and London-based Intrepid Growth Partners announced the final close of its inaugural fund at US$525 million (about C$730 million), US$25 million above target, on 14 Septem…
Axle AI lands $17.5M Series A for AI-native insurance backend
New York insurtech Axle AI announced a $17.5M Series A on Sept 3, 2026, led by Base10 Partners. Its AI agents automate claims, coverage verification and policy endorsements for ins…
Get briefs like this tuned to you.
In the app, Founder Briefs are personalized to your country, industry and stage, and you can save the ones that matter.
See plans →
Keep exploring
Related across the site
Case studyFalguni NayarNykaaCase studyJack MaAlibabaTermGross MarginThe percentage of revenue left after the direct costs of delivering your product or service, a core measure of business quality.TermMRR / ARR (Recurring Revenue)Monthly and annual recurring revenue: the predictable subscription income a business earns each month or year.TermTAM / SAM / SOM (Market Sizing)A framework for sizing your market: total demand (TAM), the slice you can serve (SAM), and the share you can realistically win (SOM).Case studyEric YuanZoom